Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Britain Courts Anthropic Amid US Defense Department Dispute 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
NESS ZIONA, Israel, Sept. 09, 2016 -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that its Chief Financial Officer, Gil Efron, and Vice President and Medical Director, Eran Schenker, will present a corporate overview at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference, taking place September 11-13 at the Lotte New York Palace Hotel in New York City.
Kamada Presentation Details
| Date: | Tuesday, September 13 | ||||
| Time: | 11:40am Eastern Time | ||||
| Location: | Lotte New York Palace Hotel | ||||
| Webcast: | http://wsw.com/webcast/rrshq26/kmda |
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia® in the U.S. through a strategic partnership with Baxalta (formerly Baxter International Inc.’s BioScience business and now part of Shire plc) and in other counties through local distributors. In addition to Glassia®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that its MAA was submitted to the EMA after completing a pivotal Phase 2/3 clinical trials in Europe. Kamada has also completed its Phase 2 clinical trials in the U.S. In addition, Kamada's intravenous AAT is in development for other indications such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.
CONTACTS: Gil Efron Chief Financial Officer [email protected] Bob Yedid LifeSci Advisors, LLC 646-597-6989 [email protected]
